16. クロウ・深瀬症候群 Crow-Fukase syndrome Clinical trials / Disease details


臨床試験数 : 13 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 75

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2200056637
2022-02-082022-02-09A multicenter, open and exploratory clinical study of pomadomide combined with dexamethasone in the treatment of newly diagnosed POEMS syndromeA multicenter, open and exploratory clinical study of pomadomide combined with dexamethasone in the treatment of newly diagnosed POEMS syndrome Multiple myelomaPd:Pomadomide combined with dexamethasone in the treatment of patients with newly diagnosed POEMS syndrome ;Qingdao Municipal HospitalNULLRecruiting18100BothPd:30;Phase 4China
2NCT02921893
(ClinicalTrials.gov)
October 31, 201626/9/2016Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeIxazomib, Lenalidomide, and Dexamethasone for Patients With POEMS SyndromePlasmacytoma;POEMS SyndromeDrug: Dexamethasone;Drug: Ixazomib Citrate;Drug: Lenalidomide;Other: Questionnaire AdministrationMayo ClinicNational Cancer Institute (NCI)Active, not recruiting18 YearsN/AAll21Early Phase 1United States
3NCT01816620
(ClinicalTrials.gov)
March 201414/3/2013Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS SyndromeAn Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS SyndromePOEMS SyndromeDrug: Lenalidomide, DexamethasonePeking Union Medical College HospitalCelgene CorporationCompleted18 YearsN/AAll41Phase 2China
4NCT01639898
(ClinicalTrials.gov)
July 20125/7/2012POEMS Syndrome Treatment With LenalidomidePhase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.POEMS SyndromeDrug: Lenalidomide and dexamethasoneUniversity Hospital, LimogesMinistry of Health, France;Celgene CorporationCompleted18 YearsN/AAll51Phase 2France
5NCT00971685
(ClinicalTrials.gov)
July 20093/9/2009The Treatment of Lenalidomide in Patients With POEMS SyndromeEvaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS SyndromePOEMS SyndromeDrug: Lenalidomide and dexamethasoneIstituto Clinico HumanitasNULLRecruiting18 YearsN/ABoth16Phase 2Italy